The Joint Corp. (JYNT) vs Milestone Pharmaceuticals Inc. (MIST)
A side-by-side comparison of The Joint Corp. and Milestone Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
JYNT
The Joint Corp.
$7.10HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT
MIST
Milestone Pharmaceuticals Inc.
$0.77HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT
Total return — JYNT vs MIST
growth of $100 · dividends reinvested · last 7yJYNT -59.3% (-12.0%/yr)MIST -94.9% (-34.7%/yr)JYNT compounded faster over this window
Log scale — wide-divergence pair
JYNT MIST
JYNT vs MIST: by the numbers
- •JYNT is the larger company ($101M vs $96M market cap).
- •JYNT is profitable (6.49% net margin) while MIST runs a net loss (-3585.62%).
- •Both shrank revenue over the past five years; JYNT's decline was smaller (-3.57% vs -31.02% CAGR).
Metrics side by side
Valuation
| Metric | JYNT | MIST |
|---|---|---|
| P/E ratio | 26.78 | N/A |
| Forward P/E | 29.58 | N/A |
| P/S ratio | 1.73 | 40.95 |
| P/B ratio | 6.39 | 5.27 |
| EV / EBITDA | 25.66 | N/A |
| FCF yield | 4.18% | N/A |
Profitability
| Metric | JYNT | MIST |
|---|---|---|
| Gross margin | 81.08% | 94.58% |
| Operating margin | 2.45% | -4041.72% |
| Net margin | 6.49% | -3585.62% |
| ROE | 23.96% | -461.14% |
| ROIC | 5.11% | -49.27% |
Growth (annualized)
| Metric | JYNT | MIST |
|---|---|---|
| Revenue CAGR (5Y) | -3.57% | -31.02% |
| EPS CAGR (5Y) | -27.37% | N/A |
| FCF CAGR (5Y) | -16.35% | N/A |
| Total return CAGR (5Y) | -40.34% | -33.18% |
Frequently asked
- Which has grown faster, JYNT or MIST?
- Neither grew: over the past five years both shrank revenue, with JYNT's decline the smaller — JYNT at a -3.57% CAGR versus MIST at -31.02%.
- Is JYNT or MIST more profitable?
- JYNT runs the higher net margin — JYNT at 6.49% versus MIST at -3585.62%.
- How have JYNT and MIST total returns compared?
- Over the past 5 years, JYNT delivered -40.34% and MIST delivered -33.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Joint P/E ratioJoint ROEMilestone Pharmaceuticals ROEJoint operating marginMilestone Pharmaceuticals operating marginJoint revenue growthMilestone Pharmaceuticals revenue growthJoint free cash flowMilestone Pharmaceuticals free cash flow
Joint & Milestone Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.